Bailard Inc. increased its stake in Regeneron Pharmaceuticals by 10.1% in Q4, raising its holdings to 13,422 shares.
If brands integrating AI imagery into their ads do it in a way that feels generic, uninspired or deceptive, audiences may ...
3d
Hosted on MSNRegeneron makes second bid for blood cancer therapy approvalThe FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Ten out of 11 children with a form of congenital deafness who were treated with an experimental gene therapy developed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results